The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...

BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...

At Frontiers Health 2025, the conversation around global brand launches was evolving rapidly – and EVERSANA and its agency ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing ...